Fonseca, P. E. O. (2024) “Benefits of using SLGT2 Inhibitors for Patients with CDK and DM2 to Reduce Mortality Risks”, Archives of Pharmacy and Pharmaceutical Sciences, 8(1), pp. 041–046. doi: 10.29328/journal.apps.1001055.